He Zhicheng, Xia Yang, Tang Shaowen, Chen Yijiang, Chen Liang
1 Department of Thoracic Surgery, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 2 Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 210029, China.
J Thorac Dis. 2016 Mar;8(3):375-85. doi: 10.21037/jtd.2016.02.52.
patients of pN0 non-small cell lung cancer (NSCLC) with occult tumor cells (OTCs) in regional lymph nodes (LNs) are reported to have controversial prognostic outcomes.
We pooled pN0 NSCLC patients with OTCs in LNs and compared with those without OTCs. Patient characteristics, hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and/or disease-free survival (DFS) were analyzed. HR greater than 1 conferred an increased hazard for patients with OTCs.
Eighteen articles were finally enrolled in the meta-analysis and 15 studies provided sufficient data for extracting HRs for OS, resulting to 5 articles available for DFS analysis. The combined HRs of OS was 2.22 (95% CI, 1.87 to 2.64) and 2.4 (95% CI, 1.71 to 3.36) for analysis of DFS. The similar trend was obtained in the subgroup analyses regarding detection methods and study type. Interestingly, even in the analysis of mean numbers of LNs dissection (MLND) intraoperatively, both subgroups (LNs/Pts. <12 and ≥12) illustrated significant HRs of OS (HR: 3.13, 95% CI, 2.17 to 4.52 in LNs/Pts. <12 subgroup and HR: 2.09, 95% CI, 1.63 to 2.68 in LNs/Pts. ≥12). The combined HR of OS in this section was 2.37 (95% CI, 1.63 to 2.68). No publication bias was detected in all the meta-analysis sections. The prognosis of patients with OTCs is inferior to those without OTCs in the terms of OS and DFS regardless of detection methods, study types and MLND.
The prognosis of patients with OTCs is inferior to those without OTCs in the terms of OS and DFS regardless of detection methods, study types and MLND.
据报道,区域淋巴结(LN)中存在隐匿肿瘤细胞(OTC)的pN0非小细胞肺癌(NSCLC)患者的预后结果存在争议。
我们汇总了LN中存在OTC的pN0 NSCLC患者,并与无OTC的患者进行比较。分析了患者特征、总生存期(OS)和/或无病生存期(DFS)的风险比(HR)及95%置信区间(CI)。HR大于1表明存在OTC的患者风险增加。
最终纳入荟萃分析的有18篇文章,15项研究提供了足够的数据用于提取OS的HR,5篇文章可用于DFS分析。OS的合并HR为2.22(95%CI,1.87至2.64),DFS分析的HR为2.4(95%CI,1.71至3.36)。在关于检测方法和研究类型的亚组分析中也得到了类似趋势。有趣的是,即使在术中分析平均淋巴结清扫数(MLND)时,两个亚组(LN/患者<12和≥12)的OS均显示出显著的HR(LN/患者<12亚组中HR:3.13,95%CI,2.17至4.52;LN/患者≥12亚组中HR:2.09,95%CI,1.63至2.68)。该部分OS的合并HR为2.37(95%CI,1.63至2.68)。在所有荟萃分析部分均未检测到发表偏倚。无论检测方法、研究类型和MLND如何,存在OTC的患者在OS和DFS方面的预后均劣于无OTC的患者。
无论检测方法、研究类型和MLND如何,存在OTC的患者在OS和DFS方面的预后均劣于无OTC的患者。